E

What was old in cancer research is new again

A fresh look at a class of targeted therapy agents that are beginning to look promising in some cancer patients

September 13, 2018
E

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018
E

Targeting immunosuppression and other stories – are we ready for prime time yet?

On targeting immunosuppression and some obscure oncogenic targets

August 9, 2018
E

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018
E

An up and coming IO target to watch out for

Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...

July 19, 2018
E

Adapting TCR therapies for different solid tumours

An in-depth look at Adaptimmune's TCR T cell therapy program

July 10, 2018
E

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018
E

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018
E

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018
E

A beautiful day

Update on TLR9 as a target and what we learn from the latest clinical data

June 12, 2018
E

Fitting it all together – what does the post ASCO Lung Cancer Landscape look like?

Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...

June 11, 2018
E

ASCO18 Review of targeted therapies and combination approaches

Highlights and Lowlights amongst targeted therapy data at ASCO 2018

June 7, 2018
E

ASCO18 Day 3 Highlights and Lowlights

Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.

June 5, 2018
E

Will KEYNOTE-042 change the standard of care in lung cancer?

Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).

June 3, 2018
E

ASCO18 Day 1 Highlights

The promise and pitfalls of Day 1 of #ASCO18

June 3, 2018
E

Why don’t all cancer patients with a high TIL respond to immunotherapy?

We explore the importance of looking under the hood at various expression levels...

May 30, 2018
E

Learning from IO-IO combo misses

Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?

May 29, 2018
E

ASCO18 Reader Q&A

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…

May 25, 2018
E

ASCO18 Preview on Biomarkers of Response

Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?

May 22, 2018
E

ASCO18 Preview 4 What’s Hot in Urothelial Carcinoma

A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18

May 21, 2018
E

ASCO18 Preview 3 – Take a Walk on Life

What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen

May 18, 2018
E

ASCO18 Preview 2 – a dozen key Posters to watch out for

Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?

May 16, 2018
E

ASCO18 Preview 1 – Magnificence or Atrocious?

What to watch out for at ASCO18 in the oral presentation sessions

May 15, 2018
E

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018